Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now?

May 4, 2026 - 04:01

A new bullish thesis on Hims & Hers Health, Inc. has surfaced on an investment ideas substack, written by Antonio Linares. The analysis makes a case for why the company might be worth a closer look for investors. As of April 21st, HIMS shares were trading at $29.76, and the thesis examines both the trailing and forward potential of the business.

Hims & Hers has carved out a unique space in the telehealth and direct-to-consumer healthcare market. The company focuses on making treatments for hair loss, mental health, sexual health, and skincare more accessible through an online platform. The bullish argument centers on the company's rapid revenue growth and its ability to scale without the heavy overhead of traditional healthcare providers. By removing the need for in-person visits and leveraging a subscription model, Hims & Hers has built a recurring revenue stream that investors find attractive.

The thesis also points to the company's expanding product offerings and its move into weight management, which is a massive addressable market. With a younger, digitally native customer base, the company is positioned to capture a significant share of consumers who prefer managing their health online. The current share price, according to the analysis, does not fully reflect this growth trajectory.

However, potential risks remain. The telehealth space is becoming crowded, and regulatory changes could impact how the company operates. Competition from both established healthcare firms and other digital startups could pressure margins. For now, the bullish case suggests that HIMS has strong momentum, but investors should weigh the growth story against the competitive landscape and valuation concerns.